Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy

Cette étude analyse le rôle thérapeutique des greffes de cellules souches hématopoïétiques autologues et allogéniques chez des patients atteints de leucémies aiguës, de lymphomes agressifs à cellules B et de myélomes multiples et examine la place de ce traitement vis-à-vis des nouvelles thérapies ciblées et des immunothérapies

Résumé en anglais

Hematopoietic stem cell transplantation (HCT) has been an integral component in the treatment of many hematologic malignancies. Since the development of HCT nearly 50 years ago, the role of this modality has evolved as newer treatment approaches have been developed and integrated into the standard of care. In the last decade, novel and highly active targeted therapies and immunotherapies have been approved for many hematologic malignancies, raising the question of whether HCT continues to retain its prominent role in the treatment paradigms of various hematologic malignancies. In this review, the authors have described the current role of autologous and allogeneic HCT in the treatment of patients with acute leukemias, aggressive B-cell lymphomas, and multiple myeloma and discussed how novel targeted therapies and immunotherapies have changed the potential need, timing, and goal of HCT in patients with these diseases.